These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 36101479)
1. Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first- and second-line ART in Tanzania. Henerico S; Lyimo E; Makubi AN; Magesa D; Desderius B; Mueller A; Changalucha J; Kalluvya SE; Van Zyl G; Preiser W; Mshana SE; Kasang C J Antimicrob Chemother; 2022 Oct; 77(11):3138-3143. PubMed ID: 36101479 [TBL] [Abstract][Full Text] [Related]
2. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance. Tzou PL; Rhee SY; Descamps D; Clutter DS; Hare B; Mor O; Grude M; Parkin N; Jordan MR; Bertagnolio S; Schapiro JM; Harrigan PR; Geretti AM; Marcelin AG; Shafer RW; J Antimicrob Chemother; 2020 Jan; 75(1):170-182. PubMed ID: 31617907 [TBL] [Abstract][Full Text] [Related]
3. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India. Karade S; Sen S; Sashindran VK AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915 [TBL] [Abstract][Full Text] [Related]
4. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort. Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149 [TBL] [Abstract][Full Text] [Related]
5. Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia. Arimide DA; Szojka ZI; Zealiyas K; Gebreegziabxier A; Adugna F; Sasinovich S; Björkman P; Medstrand P Viruses; 2022 Mar; 14(4):. PubMed ID: 35458459 [TBL] [Abstract][Full Text] [Related]
6. HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-naïve adult patients in Luanda, Angola. Sebastião CS; Abecasis AB; Jandondo D; Sebastião JMK; Vigário J; Comandante F; Pingarilho M; Pocongo B; Cassinela E; Gonçalves F; Gomes P; Giovanetti M; Francisco NM; Sacomboio E; Brito M; Neto de Vasconcelos J; Morais J; Pimentel V Sci Rep; 2024 Jul; 14(1):15893. PubMed ID: 38987263 [TBL] [Abstract][Full Text] [Related]
7. Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda. McCluskey SM; Kamelian K; Musinguzi N; Kigozi S; Boum Y; Bwana MB; Muzoora C; Brumme ZL; Carrington M; Carlson J; Foley B; Hunt PW; Martin JN; Bangsberg DR; Harrigan PR; Siedner MJ; Haberer JE; Lee GQ AIDS; 2021 Jun; 35(7):1083-1089. PubMed ID: 33635845 [TBL] [Abstract][Full Text] [Related]
8. Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018-2020). Yang Z; Yang X; Deng X; Wei S; Liu J; Ma J; Zhao Q; Huo Y Infection; 2021 Dec; 49(6):1195-1202. PubMed ID: 34279816 [TBL] [Abstract][Full Text] [Related]
9. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda. Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364 [TBL] [Abstract][Full Text] [Related]
10. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1. Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors. Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM; J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378 [TBL] [Abstract][Full Text] [Related]
12. Circulating HIV-1 Integrase Genotypes in Tanzania: Implication on the Introduction of Integrase Inhibitors-Based Antiretroviral Therapy Regimen. Masoud S; Kamori D; Barabona G; Mahiti M; Sunguya B; Lyamuya E; Ueno T AIDS Res Hum Retroviruses; 2020 Jun; 36(6):539-543. PubMed ID: 32126792 [TBL] [Abstract][Full Text] [Related]
13. Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings. Semengue ENJ; Armenia D; Inzaule S; Santoro MM; Dambaya B; Takou D; Teto G; Nka AD; Yagai B; Fabeni L; Chenwi C; Angong Beloumou G; Djupsa Ndjeyep SC; Colizzi V; Perno CF; Ceccherini-Silberstein F; Fokam J J Antimicrob Chemother; 2021 Apr; 76(5):1277-1285. PubMed ID: 33501504 [TBL] [Abstract][Full Text] [Related]
14. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe. de Salazar A; Viñuela L; Fuentes A; Teyssou E; Charpentier C; Lambert-Niclot S; Serrano-Conde E; Pingarilho M; Fabeni L; De Monte A; Stefic K; Perno CF; Aguilera A; Falces I; Delgado R; Fernandes S; Diogo I; Gomes P; Paraskevis D; Santoro MM; Ceccherini-Silberstein F; Marcelin AG; Garcia F Clin Infect Dis; 2023 May; 76(9):1628-1635. PubMed ID: 36571282 [TBL] [Abstract][Full Text] [Related]
15. Virological outcomes of various first-line ART regimens in patients harbouring HIV-1 E157Q integrase polymorphism: a multicentre retrospective study. Uno S; Gatanaga H; Hayashida T; Imahashi M; Minami R; Koga M; Samukawa S; Watanabe D; Fujii T; Tateyama M; Nakamura H; Matsushita S; Yoshino Y; Endo T; Horiba M; Taniguchi T; Moro H; Igari H; Yoshida S; Teshima T; Nakajima H; Nishizawa M; Yokomaku Y; Iwatani Y; Hachiya A; Kato S; Hasegawa N; Yoshimura K; Sugiura W; Kikuchi T J Antimicrob Chemother; 2023 Dec; 78(12):2859-2868. PubMed ID: 37856677 [TBL] [Abstract][Full Text] [Related]
16. Prevalence and analysis of acquired and transmitted integrase strand transfer inhibitor-associated HIV-1 drug resistance in Chongqing, China. Zhang H; Wu P; Li J; Li M Virulence; 2023 Dec; 14(1):2278254. PubMed ID: 37941373 [TBL] [Abstract][Full Text] [Related]
17. HIV-1 Genetic Diversity and Natural Polymorphisms of the Integrase Gene in Integrase Inhibitor-Naive Patients in Harare, Zimbabwe. Madyadi A; Dhoro M; Shamu T; Washaya T; Kouamou V; Chimukangara B; Katzenstein D; Manasa J AIDS Res Hum Retroviruses; 2021 Dec; 37(12):954-961. PubMed ID: 34714124 [TBL] [Abstract][Full Text] [Related]
18. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance. Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878 [TBL] [Abstract][Full Text] [Related]
19. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. Zhao AV; Crutchley RD; Guduru RC; Ton K; Lam T; Min AC Retrovirology; 2022 Oct; 19(1):22. PubMed ID: 36273165 [TBL] [Abstract][Full Text] [Related]